Your browser doesn't support javascript.
loading
Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.
Heyckendorf, Jan; Georghiou, Sophia B; Frahm, Nicole; Heinrich, Norbert; Kontsevaya, Irina; Reimann, Maja; Holtzman, David; Imperial, Marjorie; Cirillo, Daniela M; Gillespie, Stephen H; Ruhwald, Morten.
Afiliação
  • Heyckendorf J; Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Georghiou SB; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
  • Frahm N; German Center for Infection Research (DZIF), Braunschweig, Germany.
  • Heinrich N; International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
  • Kontsevaya I; FIND, the Global Alliance for Diagnostics, Geneva, Switzerland.
  • Reimann M; Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA.
  • Holtzman D; Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich (LMU), Munich, Germany.
  • Imperial M; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
  • Cirillo DM; German Center for Infection Research (DZIF), Braunschweig, Germany.
  • Gillespie SH; International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
  • Ruhwald M; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Clin Microbiol Rev ; 35(3): e0022721, 2022 09 21.
Article em En | MEDLINE | ID: mdl-35311552
ABSTRACT
Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success. Current recommendations for TB treatment monitoring rely on sputum and culture conversion, which have low sensitivity and long turnaround times, present biohazard risk, and are prone to contamination, undermining their usefulness as clinical treatment monitoring tools and for drug development. We review the pipeline of molecular technologies and assays that serve as suitable substitutes for current culture-based readouts for treatment response and outcome with the potential to change TB therapy monitoring and accelerate drug development.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Mycobacterium tuberculosis Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Mycobacterium tuberculosis Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha